drugset
drugset / Trial / NCT06356259

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

NCT06356259 ↗

Phase 1 Terminated 83 enrolled ImmunoRx Pharma Inc.
RandomizedSequentialDouble-blindBasic science

Summary

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics with intravenous(IV) administration of IRX-010 in Healthy Participants.

Timeline

Start
2023-06-07
Primary completion
2025-01-23
Completion
2025-01-23

Outcome

Outcome not reported

Stopped: “The highest multiple dose planned for this study was not well tolerated by most participants. There is no benefit to continue dosing of healthy participants.”

Drugs

EvaluationDrugModalityDoseRoute
Subject IRX-010 Unknown — Intravenous

Indications

No indication recorded.